Physician profile
Leon Buffaloe
NPI 1366603391
$5,982.62
in general payments reported to CMS, 2019-2025
46 companies · $914 in 2025
The $914 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.46 · 2020: $37.44 · 2021: $1,334 · 2022: $1,622 · 2023: $794 · 2024: $1,226 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.95 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $836.73 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $803.25 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $549.49 | 2021-2025 | |
| Dexcom, INC. | $296.69 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $292.84 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $227.79 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $167.73 | 2020-2023 | |
| Astellas Pharma US INC | $155.85 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $152.07 | 2021-2024 | |
| Daiichi Sankyo INC. | $132.81 | 2022-2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $117.90 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.53 | 2021-2023 | Synjardy, Tradjenta |
| Amarin Pharma, INC. | $99.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $98.23 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Buffaloe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.